45 related articles for article (PubMed ID: 19732200)
1. Modelling cost-effectiveness of high-dose chemotherapy as treatment for relapsed aggressive non-Hodgkin lymphoma in an Australian setting.
Prajogo J; Neil A; Duke J; Zhang H; Stokes B; Rowlings P
Intern Med J; 2009 Aug; 39(8):519-26. PubMed ID: 19732200
[TBL] [Abstract][Full Text] [Related]
2. MODELING COST-EFFECTIVENESS OF HIGH DOSE CHEMOTHERAPY AS TREATMENT FOR RELAPSED AGGRESSIVE NON-HODGKIN'S LYMPHOMA IN AN AUSTRALIAN SETTING.
Prajogo J; Neil A; Duke J; Zhang H; Stokes B; Rowlings P
Intern Med J; 2009 Jun; ():. PubMed ID: 19519757
[TBL] [Abstract][Full Text] [Related]
3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
4. Cost determinants in aggressive non-Hodgkin's lymphoma.
van Agthoven M; Sonneveld P; Verdonck LF; Uyl-de Groot CA
Haematologica; 2005 May; 90(5):661-71. PubMed ID: 15921381
[TBL] [Abstract][Full Text] [Related]
5. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges.
Lokich JJ; Moore CL; Anderson NR
Cancer; 1996 Jul; 78(2):294-9. PubMed ID: 8674006
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of autologous bone marrow transplantation in patients with relapsed non-Hodgkin's lymphoma.
Messori A; Bonistalli L; Costantini M; Alterini R
Bone Marrow Transplant; 1997 Feb; 19(3):275-81. PubMed ID: 9028558
[TBL] [Abstract][Full Text] [Related]
7. Comparison of peripheral blood progenitor cell yield from standard chemotherapy used in the treatment of lymphoid malignancies and high-dose cyclophosphamide: a retrospective review of 141 patients.
Assouline S; Sylvestre MP; Carriere P; Shustik C; Laneuville P
Transfusion; 2006 Feb; 46(2):174-9. PubMed ID: 16441591
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma.
Beard SM; Lorigan PC; Sampson FC
Br J Cancer; 2000 Jan; 82(1):81-4. PubMed ID: 10638970
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma.
Doorduijn JK; Buijt I; van der Holt B; van Agthoven M; Sonneveld P; Uyl-de Groot CA
Haematologica; 2004 Sep; 89(9):1109-17. PubMed ID: 15377472
[TBL] [Abstract][Full Text] [Related]
10. High-dose chemotherapy for patients with high-risk breast cancer: a clinical and economic assessment using a quality-adjusted survival analysis.
Marino P; Roché H; Moatti JP;
Am J Clin Oncol; 2008 Apr; 31(2):117-24. PubMed ID: 18391594
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the cost effectiveness of concurrent cisplatin-based chemoradiation in cervical cancer: implications from five randomized trials.
Rose PG; Lappas PT
Gynecol Oncol; 2000 Jul; 78(1):3-6. PubMed ID: 10873400
[TBL] [Abstract][Full Text] [Related]
12. Treatments for newly diagnosed advanced ovarian cancer: analysis of survival data and cost-effectiveness evaluation.
Messori A; Trippoli S; Becagli P; Tendi E
Anticancer Drugs; 1998 Jul; 9(6):491-502. PubMed ID: 9877236
[TBL] [Abstract][Full Text] [Related]
13. The cost of treating relapsed indolent non-Hodgkin's lymphoma in an international setting: retrospective analysis of resource use.
Herold M; Sacchi S; Hieke K
Haematologica; 2002 Jul; 87(7):719-29; discussion 729. PubMed ID: 12091123
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden.
Kasteng F; Erlanson M; Hagberg H; Kimby E; Relander T; Lundkvist J
Acta Oncol; 2008; 47(6):1029-36. PubMed ID: 18607857
[TBL] [Abstract][Full Text] [Related]
15. High-dose chemotherapy and peripheral blood stem cell infusion in patients with non-Hodgkin's lymphoma: results of outpatient treatment in community cancer centers.
Weaver CH; Schwartzberg L; Zhen B; Mangum M; Leff R; Tauer K; Rosenberg A; Pendergrass K; Kaywin P; Hainsworth J; Greco FA; West WH; Buckner CD
Bone Marrow Transplant; 1997 Nov; 20(9):753-60. PubMed ID: 9384477
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Reed SD; Anstrom KJ; Ludmer JA; Glendenning GA; Schulman KA
Cancer; 2004 Dec; 101(11):2574-83. PubMed ID: 15493042
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
[TBL] [Abstract][Full Text] [Related]
18. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.
Hornberger JC; Best JH
Cancer; 2005 Apr; 103(8):1644-51. PubMed ID: 15756658
[TBL] [Abstract][Full Text] [Related]
19. Consolidative involved field radiotherapy after high dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma: a case-control study.
Oehler-Jänne C; Taverna C; Stanek N; Negretti L; Lütolf UM; Ciernik IF
Hematol Oncol; 2008 Jun; 26(2):82-90. PubMed ID: 18085574
[TBL] [Abstract][Full Text] [Related]
20. Cost-analysis of high-dose chemotherapy and peripheral blood stem-cell support in patients with solid tumors.
Astier MP; Mayordomo JI; Abad JM; Gómez LI; Tres A
Ann Oncol; 2000 May; 11(5):603-6. PubMed ID: 10907956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
